Latest News - SciFluor Life Sciences

Monday, December 18, 2017 | Clinical Trials, Retina, SciFluor Life Sciences

SciFluor Announces Positive Topline Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet AMD

SciFluor Life Sciences announced positive topline results of a phase 1/2 trial studying the treatment of wet age-related macular degeneration (AMD) patients with SF0166, the company’s lead eye d…

Read the full story

Wednesday, December 13, 2017 | Patents, SciFluor Life Sciences

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases

SciFluor Life Sciences announced that the European Patent Office has issued a patent (EP 2953948) for SF0166, a novel potent and selective small molecule inhibitor of integrin αvβ3, in reti…

Read the full story

Thursday, September 28, 2017 | Clinical Trials, SciFluor Life Sciences

SciFluor Announces Positive Topline Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in DME Patients

SciFluor Life Sciences, a subsidiary of Allied Minds, announced positive topline results of a phase 1/2 study of SF0166, the company’s lead drug in development for the topical (eye drop) treatme…

Read the full story

Wednesday, October 19, 2016 | Clinical Trials, SciFluor Life Sciences

SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution

SciFluor Life Sciences announced that the first patients have been dosed in both phase 1/2 trials of SF0166 topical ophthalmic solution. This represents an important step forward in the clinical inves…

Read the full story

Monday, August 01, 2016 | Clinical Trials, SciFluor Life Sciences

SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases

SciFluor Life Sciences announced that the investigational new drug (IND) application to the FDA is now in effect for SF0166 topical ophthalmic solution (SF0166). This enables the company to initiate c…

Read the full story